<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4032">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054428</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1526</org_study_id>
    <secondary_id>2015-004458-16</secondary_id>
    <nct_id>NCT03054428</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dupilumab in Patients ≥12 to &lt;18 Years of Age, With Moderate-to-Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to &lt;18 Years of Age, With Moderate-to-severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of dupilumab as a monotherapy in patients ≥12 years to &lt;18 years
      of age with moderate-to-severe atopic dermatitis (AD)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Investigator Global Assessment (IGA) 0 to 1 (on a 5-point scale) (For US and ex-US)</measure>
    <time_frame>At week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with Eczema Area and Severity (EASI) EASI-75 (≥75% improvement from baseline) (For ex-US)</measure>
    <time_frame>At week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with EASI-75 (≥75% improvement from baseline) (for US)</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in EASI score</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in weekly average of daily peak Pruritus Numerical Rating Scale (NRS)</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (reduction) of weekly average of daily peak Pruritus NRS ≥4</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly average of daily peak Pruritus NRS</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (reduction) of weekly average of daily peak Pruritus NRS ≥3</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with EASI-50</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with EASI-90</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent body surface area (BSA) affected by AD</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Children's Dermatology Life Quality Index (CDLQI)</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in weekly average of daily peak Pruritus (NRS)</measure>
    <time_frame>Baseline to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (reduction) of weekly average of daily peak Pruritus NRS ≥4</measure>
    <time_frame>Baseline to week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of skin-infection treatment-emergent adverse events (TEAEs) (excluding herpetic infections)</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious TEAEs</measure>
    <time_frame>Baseline to week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Moderate-to-Severe Atopic Dermatiti</condition>
  <condition>Dermatitis, Dermatitis Atopic</condition>
  <condition>Eczema, Skin Diseases, Skin</condition>
  <condition>Diseases Genetic, Genetic</condition>
  <condition>Diseases Inborn, Skin</condition>
  <condition>Disease, Eczematous Skin</condition>
  <condition>Hypersensitivity, Immediate</condition>
  <condition>Hypersensitivity, Immune System Diseases</condition>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 1 - Drug: Dupilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 2 - Drug: Dupilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 3 - Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Dupilumab as per protocol</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥12 to &lt;18 years of age at time of screening visit

          -  Diagnosis of AD according to the American Academy of Dermatology consensus criteria
             at screening visit

          -  IGA ≥3 at screening and baseline visit

          -  EASI ≥16 at the screening and baseline visit

          -  Baseline Pruritus Numerical Rating Scale (NRS) average score for maximum itch
             intensity ≥4

          -  ≥10% body surface area (BSA) of AD involvement at the screening and baseline visits

          -  With documented recent history (within 6 months before the screening visit) of
             inadequate response to topical AD medication(s) or for whom topical treatments is
             medically inadvisable

        Exclusion Criteria:

          -  Participation in a prior dupilumab clinical study

          -  Treatment with TCS or topical calcineurin inhibitors (TCI) within 2 weeks before the
             baseline visit

          -  Having used immunosuppressive/immunomodulating drugs within 4 weeks before the
             baseline visit

          -  Body weight &lt;30 kg at Baseline

          -  Active chronic or acute infection requiring treatment with systemic antibiotics,
             antivirals, antiprotozoals, or antifungals within 2 weeks before the baseline visit

          -  Known or suspected immunodeficiency, known history of human immunodeficiency virus
             (HIV) infection or HIV seropositivity at the screening visit, established diagnosis
             of HBV infection or HBV seropositivity at screening, established diagnosis of HCV
             infection or HCV seropositivity at screening

          -  History of malignancy before the baseline visit

          -  Diagnosed active endoparasitic infections or at high risk of these infections

          -  Patient is female who is pregnant, breastfeeding, or planning to become pregnant or
             breastfeed during the study

          -  Patient is female of childbearing potential and sexually active, who is unwilling to
             use adequate methods of contraception throughout the duration of the study and for
             120 days after the last dose of study drug

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>February 13, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Hypersensitivity, Immediate</mesh_term>
    <mesh_term>Skin Diseases, Eczematous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
